2 Jan, 2025

Could a single pill crack the code of treating Alzheimer’s disease?

alzheon2025-01-04T15:43:38-05:00January 2nd, 2025|

Read More

24 Jun, 2024

Alzheon nabs $100M in series E to advance oral Alzheimer’s drug

alzheon2024-06-26T15:07:42-04:00June 24th, 2024|Tags: BioWorld|

Read More

12 Jun, 2024

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing

alzheon2024-06-14T12:13:01-04:00June 12th, 2024|Tags: GEN|

Read More

12 Jun, 2024

With fresh $100M, Alzheon lays out strategy for Alzheimer’s approval next year

alzheon2024-06-14T12:25:50-04:00June 12th, 2024|Tags: Firstword Pharma|

Read More

11 Jun, 2024

Breakthroughs in Alzheimer Research Pave Way for New Era of Treatment: Martin Tolar, MD, PhD

alzheon2024-06-26T14:05:46-04:00June 11th, 2024|

Read More

2 Apr, 2024

Beginning a New Era of Precision Alzheimer’s Therapeutics

alzheon2024-06-03T14:44:54-04:00April 2nd, 2024|Tags: Inside Precision Medicine|

Read More

11 Jan, 2024

Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc. January 2024

alzheon2024-06-03T14:42:41-04:00January 11th, 2024|Tags: Newsweek|

Read More

22 Sep, 2023

ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s

alzheon2023-10-02T11:49:22-04:00September 22nd, 2023|

Read More

18 Sep, 2023

Alzheimer Agent ALZ-801 Improves Cognition, Reduces Relevant Biomarker Levels in 2-Year Analysis

alzheon2023-09-21T10:37:23-04:00September 18th, 2023|

Read More

16 Jul, 2023

AAIC: A Pill to Slow Down Alzheimer’s Is About Two Years Away

alzheon2023-07-18T10:41:12-04:00July 16th, 2023|

Read More